Mushroom Biotechnology

Conflicts of Interest The author declares no conflict of interest. References 1 and , “Medicinal Mushrooms: Past, Present and Future,” Advances in Biochemical Engineering/Biotechnology 184 (2023): 1–27. 2, “Hericium Erinaceus: The Enchanting Medicinal-Culinary Mushroom of East Asian Tradition,” Integrative Medicine Discovery 8 (2024): e24013. 3, , , and , “Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials,” International Journal of Molecular Sciences 22 (2021): 634.

Supporting Information Filename Description ppl70204-sup-0001-supinfo.pdfPDF document, 626.4 KB Data S1: Supporting Information. REFERENCES (1984) Catalase in vitro. Methods in Enzymology 105: 121–126. , , (2010) Fine and coarse regulation of reactive oxygen species in the salt tolerant mutants of barnyard grass and their wild-type parents under salt stress. Physiologia Plantarum 138: 60–73. (2022) A natural anthraquinone plants with multi-pharmacological activities.

Conflicts of Interest The authors declare no conflicts of interest. References 1, , , and , “Metabolic Modulation: A New Therapeutic Target in Treatment of Heart Failure,” American Journal of Therapeutics 18 (2011): e197–e201. 2, , , , and , “Trimetazidine and Other Metabolic Modifiers,” European Cardiology Review 13 (2018): 104. 3, , , and , “Story Behind Meldonium—From Pharmacology to Performance Enhancement: A Narrative Review,” British Journal of Sports Medicine 51 (2017): 22–25.